Video

Dr. Lesser on Armodafinil for Radiation-Induced Fatigue

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for brain radiation-induced fatigue.

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for radiation-induced fatigue in patients with brain tumors.

Fortunately, Lesser says, researchers were able to look at a variety of endpoints in the phase II double-blind placebo-controlled study. Sleepiness, time spent sleeping, and other quality of life metrics standardized in the field were analyzed.

In the study, the group as a whole did not seem to benefit from armodafinil. However, the half of the population with lower initial quality of life scores did see a marked, statistically significant benefit when armodafinil was added to radiation therapy.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP